Objective The aim of this study was to determine the epidemiological characteristics of never-smoking patients with non-small cell lung cancer (NSCLC) detected with clinic-based screening programs, focusing on clinical risk factors and survival. Methods The medical records of NSCLC patients (n=285) diagnosed at Fujisawa City Hospital between April 2000 and December 2010 with lesions that were originally detected with clinic-based screening programs in Fujisawa City were reviewed to identify the clinicopathological variables and survival outcomes. Results Of the 285 NSCLC patients, 95 (33.3%) were never-smokers. A comparison between the neversmoking and ever-smoking patients revealed that the never-smokers included a significantly greater proportion of women and patients with adenocarcinoma (86.3% vs. 12.6%: p<0.001 or 94.7% vs. 55.8%: p<0.001, respectively). The overall survival rate of the never-smoking patients was significantly superior to that of the ever-smokers (p=0.004). In addition to smoking status, factors found to be significantly associated with the overall survival rate in univariate analyses were gender, stage, histology and first line treatment. A multivariate analysis revealed smoking status to be an independent prognostic factor in addition to stage and first line treatment. Conclusion The differences in the clinicopathological factors and survival outcomes between neversmoking and ever-smoking patients with NSCLC detected with clinic-based screening programs suggest that persuading people to never start smoking is important.
Introduction
Primary lung cancer is one of the most common cancers worldwide. In Japan, the mortality rate of lung cancer has consistently increased since the late 1,900 s, and lung cancer is currently the leading cause of cancer death in men and the second leading cause of cancer death in women (1, 2) . The use of lung cancer screening with periodic chest radiography has resulted in the detection of early stage disease, in-creased rates of resectability and improvements in lung cancer-specific survival rates (3) (4) (5) (6) (7) . Case-controlled studies conducted in Japan reveal that the currently available screening system decreases the risk of lung cancer death by 30-60% (5, 6) . Clinic-based screening programs for lung cancer implemented by general physicians were established in Fujisawa City in 1991 and in Hiratsuka City in 1984. Clinicbased screenings in Kanagawa Prefecture, Japan have significantly reduced the risk of lung cancer death (7) .
Cigarette smoking was established as a risk factor for
Figure.
Overall survival analyses for never-and ever-smoker patients with NSCLC found in clinic-based screening programs (p = 0.004). NSCLC indicates non-small cell lung cancer. 72.5 (6.8) lung cancer in the early 1950s. Additionally, smoking is associated with factors that may contribute to poor cancer survival (8) (9) (10) . Indeed, several studies have shown a positive association between smoking status and shortened survival times after treatment (11) (12) (13) (14) . There is now strong evidence that lung cancer in never-smokers shows different patterns compared to those observed in ever-smokers (15, 16) . It has been recognized that patients with non-small cell lung cancer (NSCLC) who are lifelong never-smokers constitute a distinct clinical entity (17, 18) . Only very little is known about the clinical outcomes of never-smoking patients with NSCLC detected with clinicbased screening programs (7) . The aim of this study was to assess the epidemiological characteristics of never-smoking patients with NSCLC detected with clinic-based screening programs, while focusing on clinical risk factors and survival.
Materials and Methods
This study involved 285 consecutive patients with NSCLC detected with clinic-based screening programs conducted by family physicians in Fujisawa City and diagnosed at Fujisawa City Hospital (main referral hospital) between April 2000 and December 2010. The clinic-based screening programs conducted in Fujisawa City were based on annual chest radiography screenings with or without the use of additional sputum cytological examinations (7) . The Institutional Review Board of our hospital approved this study. Patient consent was obtained for entry into the database. The information collected on the studied patients included age, gender, smoking status, pathological diagnosis, staging information, treatment and date of last follow-up or date of death.
Smoking status information was drawn from the patient's medical charts and verified with additional sources when possible. Patients with any history of smoking (current or former) were classified as "ever-smokers". "Never-smokers" were defined as those who had never smoked and were described as such in the attending physician's notes. As the history of passive exposure to environmental cigarette smoke was not consistently available, the never-smoker category did not account for passive exposure.
Overall survival was measured as the duration from the date of diagnosis to the date of death or the last contact date. The survival rates were estimated using the Kaplan-Meier method and compared between the groups by the logrank test. Multivariate analyses were performed using a Cox proportional hazards model. All statistical analyses were performed using SPSS version 16.0J for Windows (SPSS Inc., Tokyo, Japan). A two-sided p value <0.05 was considered to be statistically significant.
Results
The clinic-based screening programs conducted by family physicians in Fujisawa City between April 2000 and December 2010 found 336 NSCLC patients. Of these 336 NSCLC patients, 285 (84.8%) were diagnosed at Fujisawa City Hospital and included in our analysis. The majority were eversmokers (66.7%). Among the never-smokers (95 patients), there were significantly more women (86.3%) and patients with adenocarcinoma (94.7%) compared to the ever-smokers (12.6%: p<0.001 and 55.8%: p<0.001, respectively). There were no significant differences between never-and eversmokers with regard to age, stage, first line treatment or usage of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) ( Table 1) .
The overall survival rate of the never-smokers was significantly superior to that of the ever-smokers (p=0.004) (Figure) . The overall five-year survival rates of the neversmokers and ever-smokers were significantly different (69.1% vs. 49.0%; p=0.004). The median survival time was not determined in the never-smokers and was 58.7 months (95% CI: 33.5 to 83.9 months) in the ever-smokers. In addition to smoking status, the factors found to be significantly associated with survival were gender (female vs. male), first line treatment (resection vs. other), histological type (adenocarcinoma vs. other) and stage, as determined with univariate analyses ( Table 2) . A multivariate analysis including these prognostic factors also revealed a significant difference between never-and ever-smokers (hazards ratio=0.44, 95% CI=0.20-0.94; p=0.036) ( Table 3 ).
Discussion
Our main finding is that the prognosis of never-smoking NSCLC patients is superior to that of smoking NSCLC patients whose disease is detected with clinic-based screening programs. Several studies conducted in general clinical situations have described similar results in both early-stage surgical and non-resectable advanced-stage patients (12, 13, (19) (20) (21) .
Smoking exposure (pack-years) is a poor prognostic factor for the postoperative prognosis of patients with NSCLC. Lifelong never-smoking status has been shown to be a statistically independent factor predicting improved postoperative survival in a multivariate analysis (13) . The clinical features of never-smokers with advanced-stage non-resectable NSCLC are similar to those of patients with early-stage surgical NSCLC. The overall survival rates of lifelong neversmokers are significantly higher than those of smokers among patients with advanced-stage non-resectable NSCLC (19) . There are significant differences in survival rates between lifelong never-smokers and current smokers with mixed surgically resectable and non-resectable advanced pulmonary adenocarcinoma, and never-smoking status is a statistically significant and independent predictor of survival based on a multivariate analysis (20) . A Cox analysis of 4,954 Japanese patients with stage III or IV advanced NSCLC showed that never-smoking status is a significant favorable prognostic factor (21) . Taken together with these findings, our data confirm that never-smoking NSCLC patients exhibit superior survival rates compared to patients with smoking-related NSCLC.
Never-smokers constituted 33.3% of the NSCLC patients evaluated in our study, which is comparable with previous findings (13, 18, 19) . The proportion of patients with NSCLC who have never smoked has been reported to be 32.8% in Japan (13) , 32.4% in Singapore (18) and 24.5% in Brazil (19) . Notably, the majority of never-smoking patients are women and/or patients with adenocarcinoma. The incidence of NSCLC in never-smokers is increased among women and patients with adenocarcinoma compared to the incidence of NSCLC in never-smokers among both surgical (13) and non-resectable advanced-stage patients (17) . Both female gender and a diagnosis of adenocarcinoma have been reported to be favorable prognostic factors (22) (23) (24) . In this study, neither female gender nor a diagnosis of adenocarcinoma reached the specified significance level in the multivariate analysis, although both variables accounted for a significantly higher proportion of never-smoking patients in the univariate analysis. The multivariate analysis demonstrated that never-smoking is a statistically independent factor for improved survival, in addition to stage and first line treatment. Moreover, it has been suggested that the influence of gender and histology on survival is attributed to smoking status (17) .
The precise mechanisms that explain the survival differences observed between never-smoking and ever-smoking NSCLC patients in our study remain unclear. It has recently been reported that responses to EGFR-TKIs such as gefitinib and erlotinib are largely limited to never-smokers. Among NSCLC patients with EGFR mutations, treatment with gefitinib and erlotinib has been shown to improve the survival of patients with metastasis (25, 26) . The frequency of EGFR mutations is also inversely associated with cumulative smoking exposure (27) . However, our study failed to demonstrate any benefits of EGFR-TKIs for survival due to the limited number of patients who were assessed for EGFR mutation status and/or took EGFR-TKIs.
The limitations of our study are related to a lack of information regarding passive smoking, cooking fume exposure, comorbidities and molecular tumor analyses. We lacked assessment data regarding exposure to environmental cigarette smoke. In addition, smoking was assessed at a single timepoint. The participants may have changed their smoking use over time, which can affect lung cancer risk. We also lacked data for inhalation depth and cigarette type. However, the epidemiological behavior of our never-smoker samples confirmed the previous findings.
In conclusion, these results, together with those of published studies, emphasize the negative prognostic effects of cigarette smoking in patients with NSCLC detected with clinic-based screening programs. In order to prevent lung cancer deaths, both stopping or reducing smoking, as a part of primary prevention, and persuading people to never start smoking are important factors.
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